TSHR; | |
FFAR1; FFAR4; | |
FAAH; TDP1; RECQL; TERT; GLO1; HPGD; ALOX12; AKR1B1; HSD17B10; ALOX15; NOX4; TNKS; PARP1; TNKS2; POLB; CD38; | |
FLT3; GSK3B; | |
CA2; CA12; CA1; CA9; CA7; CA4; | |
AR; | |
PPARA; PPARD; PPARG; | |
ALOX5; MAOA; XDH; | |
KDM4E; | |
MMP9; MMP12; MMP2; | |
HIF1A; TP53; NFKB1; | |
ABCG2; | |
LMNA; RAB9A; NPC1; FABP3; FABP5; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.210E-12 | 4.812E-09 | CA1, CA12, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.716E-12 | 1.125E-08 | AR, CA1, CA12, CA2, CA4, CA7, CA9, GLO1, L3MBTL1, MMP12, MMP2, MMP9, PARP1, PPARA, PPARD, PPARG, TNKS, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.208E-10 | 5.106E-07 | CA1, CA12, CA2, CA4, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.922E-09 | 1.446E-06 | CA1, CA12, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.885E-08 | 6.412E-06 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.123E-07 | 2.983E-05 | ALOX12, ALOX15, ALOX5, HPGD |
BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 1.356E-07 | 3.515E-05 | ABCG2, AKR1B1, CA9, CD38, CYP1A1, CYP1B1, FABP3, HPGD, NFKB1, NPC1, POLB, PPARG, TP53 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.908E-07 | 4.721E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.655E-07 | 8.709E-05 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 4.457E-07 | 1.022E-04 | HPGD, MMP2, MMP9, TERT |
BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 4.753E-07 | 1.056E-04 | ALOX12, APP, CYP19A1, FFAR4, GSK3B, HIF1A, LMNA, MMP12, MMP2, NFKB1, PARP1, PPARA, PPARD, PPARG, TERT, TP53, XDH |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.384E-07 | 1.172E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 6.962E-07 | 1.486E-04 | APP, AR, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, NPC1, PPARG |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 9.948E-07 | 2.024E-04 | CYP19A1, FFAR4, NFKB1, PPARA, PPARD, PPARG |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.083E-06 | 3.943E-04 | ABCG2, APP, CD38, FLT3, HPGD, L3MBTL1, MMP9, NFKB1, PARP1, PPARG, RAB9A, SMN1, SMN2, TERT, TP53, TTR, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.730E-06 | 5.081E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 8.255E-06 | 1.303E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 8.255E-06 | 1.303E-03 | ALOX12, ALOX15 |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 1.025E-05 | 1.575E-03 | TERT, TNKS, TNKS2 |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.218E-05 | 1.817E-03 | AR, PPARA, PPARD, PPARG |
BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 1.247E-05 | 1.835E-03 | AKR1B1, AR, CA9, CD38, PARP1, PPARG |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.261E-05 | 1.843E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 1.376E-05 | 1.971E-03 | ABCG2, AKR1B1, APP, AR, CA4, CD38, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FLT3, GLO1, GSK3B, HIF1A, HSD17B10, KDM4E, L3MBTL1, LMNA, MAOA, MMP12, MMP2, NFKB1, NOX4, NPC1, PARP1, POLB, PPARA, PPARD, PPARG, RAB9A, RECQL, SMN1, SMN2, TDP1, TERT, TNKS, TNKS2, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.516E-05 | 2.115E-03 | AKR1B1, CYP19A1, CYP1A1, CYP1B1, TTR |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.525E-05 | 2.115E-03 | CYP1A1, PPARD, PPARG |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.516E-05 | 2.115E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.799E-05 | 2.418E-03 | NOX4, PARP1, POLB, TP53 |
BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 2.080E-05 | 2.664E-03 | CYP1A2, MMP9, NPC1, TERT |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.472E-05 | 3.076E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.472E-05 | 3.076E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.472E-05 | 3.076E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.561E-05 | 3.168E-03 | AR, PPARA, PPARD, PPARG |
BP | GO:0032502; developmental process | GO:0048513; animal organ development | 2.712E-05 | 3.336E-03 | AR, CA2, CYP19A1, CYP1A1, CYP1A2, FLT3, HIF1A, HPGD, L3MBTL1, POLB, PPARA, PPARD, PPARG |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.958E-05 | 3.599E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:1901564; organonitrogen compound metabolic process | 3.075E-05 | 3.679E-03 | ABCG2, AKR1B1, APP, AR, CD38, CYP1A1, CYP1A2, FLT3, GLO1, GSK3B, HIF1A, HSD17B10, KDM4E, MAOA, MMP12, MMP2, MMP9, NFKB1, NOX4, NPC1, PARP1, POLB, PPARA, PPARD, PPARG, TNKS, TNKS2, TP53, TTR, XDH |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 3.418E-05 | 4.030E-03 | HIF1A, TERT, TP53 |
BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 3.442E-05 | 4.030E-03 | APP, CYP19A1, CYP1B1, NPC1, PPARD |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.442E-05 | 4.030E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 3.858E-05 | 4.445E-03 | AKR1B1, CD38, FABP3, FFAR1, MMP2, PPARG, TP53 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.923E-05 | 4.496E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 4.013E-05 | 4.575E-03 | AR, CA2, CD38, FLT3, NPC1, PARP1 |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 4.239E-05 | 4.808E-03 | FABP3, PPARA, PPARD, PPARG |
BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 4.474E-05 | 5.019E-03 | CYP1A1, CYP1A2, PPARG |
BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 4.494E-05 | 5.019E-03 | CD38, FFAR1, HIF1A, PPARD |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.783E-05 | 5.313E-03 | CA2, CA7, HIF1A, NPC1, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 4.935E-05 | 5.373E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.935E-05 | 5.373E-03 | CYP1A1, CYP1A2 |
CC | GO:0016020; membrane | GO:0016020; membrane | 4.963E-05 | 5.377E-03 | ABCG2, ALOX12, ALOX15, ALOX5, APP, AR, CA12, CA2, CA4, CA9, CD38, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FAAH, FABP5, FFAR1, FFAR4, FLT3, GLO1, GSK3B, HPGD, HSD17B10, L3MBTL1, LMNA, MAOA, MMP2, NOX4, NPC1, PARP1, RAB9A, RECQL, TDP1, TERT, TNKS, TNKS2, TSHR |
BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 5.074E-05 | 5.416E-03 | HIF1A, PPARD, TP53 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 5.666E-05 | 5.990E-03 | AKR1B1, ALOX5, AR, FABP5, GSK3B, HIF1A, HPGD, L3MBTL1, LMNA, NFKB1, PARP1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, TERT, TNKS, TP53 |
MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 5.724E-05 | 5.992E-03 | PARP1, TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 6.264E-05 | 6.434E-03 | ALOX12, APP, CD38, FFAR4, GSK3B, HIF1A, LMNA, NFKB1, PPARD, PPARG, TERT, XDH |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 6.355E-05 | 6.478E-03 | CA2, CA7, CD38, HIF1A, NPC1, PARP1, TNKS, TNKS2 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 6.426E-05 | 6.478E-03 | PARP1, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 6.426E-05 | 6.478E-03 | APP, GSK3B, PARP1 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 7.325E-05 | 7.153E-03 | ALOX15, PPARA, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 8.209E-05 | 7.840E-03 | ALOX12, ALOX15 |
BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 8.209E-05 | 7.840E-03 | PPARA, PPARG |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 9.794E-05 | 9.060E-03 | ALOX12, ALOX15, ALOX5 |
BP | GO:0040007; growth | GO:0040008; regulation of growth | 1.010E-04 | 9.240E-03 | ALOX12, APP, AR, CD38, HIF1A, PPARD, PPARG, TNKS2, TP53 |
BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 1.055E-04 | 9.531E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0065007; biological regulation | GO:0032092; positive regulation of protein binding | 1.077E-04 | 9.694E-03 | APP, GSK3B, MMP9, TERT |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.127E-04 | 9.942E-03 | HIF1A, MMP12, MMP2, MMP9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.418E-12 | 6.274E-10 | CA12; CA1; CA2; CA4; CA7; CA9 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.339E-07 | 9.504E-06 | AR; GSK3B; FLT3; MMP2; PPARG; HIF1A; TP53; MMP9; NFKB1; PPARD |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.673E-06 | 1.659E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.406E-06 | 6.654E-05 | FABP3; FABP5; PPARG; PPARA; PPARD |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.153E-05 | 2.730E-04 | ALOX5; CYP1A1; CYP1B1; CYP19A1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.532E-05 | 3.107E-04 | APP; MAOA; ALOX5; ALOX15; ALOX12 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.093E-05 | 2.730E-04 | HPGD; FLT3; PPARG; TP53; MMP9; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.090E-05 | 3.709E-04 | CYP1A2; CYP1A1; CYP1B1; CYP19A1 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.128E-04 | 1.601E-03 | GSK3B; AR; TP53; NFKB1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.563E-04 | 5.408E-03 | MAOA; ALOX5; CYP1A2; ALOX15; CYP1A1; CD38; AKR1B1; ALOX12; CYP19A1; HSD17B10; XDH |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.055E-04 | 2.653E-03 | MMP2; MMP9; TP53 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.252E-04 | 5.408E-03 | GSK3B; PPARA; TP53; NFKB1 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 5.466E-04 | 5.408E-03 | FLT3; NFKB1; PPARD |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.370E-04 | 5.654E-03 | PARP1; LMNA; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 5.713E-04 | 5.408E-03 | GSK3B; RAB9A; TP53; NFKB1 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 7.675E-04 | 6.055E-03 | POLB; GSK3B; TERT; TP53; NFKB1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.995E-04 | 5.843E-03 | ALOX5; ALOX15; ALOX12 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.773E-04 | 6.557E-03 | FLT3; TP53; HIF1A |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.506E-03 | 1.423E-02 | MMP2; TP53; HIF1A; MMP9 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.462E-03 | 1.423E-02 | GSK3B; CD38; TP53; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.126E-03 | 7.992E-03 | CYP1A2; CYP1A1; CYP1B1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.327E-03 | 1.423E-02 | PPARG; TP53; NFKB1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.574E-03 | 1.065E-02 | CYP1A2; CYP1A1; CYP1B1 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.539E-03 | 1.795E-02 | GSK3B; PPARA; NFKB1 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.420E-03 | 2.092E-02 | GSK3B; TP53; HIF1A |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.633E-03 | 2.122E-02 | GSK3B; TP53; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.964E-03 | 3.427E-02 | TP53; MMP9; NFKB1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 7.381E-03 | 3.275E-02 | GSK3B; TP53; PPARD |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 8.731E-03 | 3.542E-02 | GSK3B; PPARA; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.554E-03 | 3.667E-02 | CYP1B1; TP53; MMP9; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.165E-02 | 4.243E-02 | APP; GSK3B; HSD17B10 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.335E-03 | 3.667E-02 | GSK3B; TP53 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.473E-02 | 4.980E-02 | TP53; NFKB1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.308E-02 | 4.642E-02 | GSK3B; TP53 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.978E-03 | 1.566E-02 | PPARG; TP53 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 8.323E-03 | 3.476E-02 | MAOA; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.431E-02 | 4.955E-02 | CYP1A2; CYP1A1 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.040E-02 | 3.886E-02 | GSK3B; TP53 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.876E-03 | 1.211E-02 | CA2; CA4 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.978E-03 | 1.566E-02 | CYP1A2; ALOX15 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 3.846E-03 | 1.883E-02 | POLB; PARP1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.659E-05 | 1.208E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARD; PPARG; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; TERT |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9; MMP9; MMP2 |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12; PPARD |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; MMP12 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; FAAH |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR; APP |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
C00-D49: Neoplasms | AML | NA | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; APP; PPARG; PPARG |
C00-D49: Neoplasms | Liver cancer | C22 | TERT |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; TERT |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; CA1; FLT3; FLT3; CA9; MMP9; NFKB1; MMP2; PARP1; GSK3B; CD38; APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MMP12; FAAH |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; PPARG |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | APP |
C00-D49: Neoplasms | Melanoma | C43 | TERT; PARP1 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; GSK3B; PPARG |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
NA: NA | Dyslipidemia | NA | PPARD |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
NA: NA | Male hypogonadism | NA | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; TERT; PARP1 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; CD38 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2; TERT |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; FAAH |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
NA: NA | Geographic retinal atrophy | NA | APP |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; AKR1B1 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
NA: NA | Edema | NA | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; TERT |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |